S3 Ep2: Experiences Gained in the Fight Against COVID-19 & Bringing the Study to the Patient

Lilly has brought its scientific and medical expertise front and center to attack the coronavirus pandemic around the world. External collaboration, speed, and expertise are key to driving solutions that help our scientists and researchers uncover new way to measure, understand, and treat diseases, especially COVID-19. The experience gained fighting a pandemic will change the way we work forever. Joe talks with Dan Skovronsky, chief scientific officer and President of Lilly Research Laboratories, about monoclonal antibodies and their role as a potential treatment for Covid. Joe also talks to Dr. Mike Cohen, co-principal investigator and director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, and Dr. Alexander Stemer, infectious disease expert and co-chair of Symphony Care Network's COVID-19 task force, about the FACTORS that inspired Lilly to “bring the study to the patients” and develop the Blaze-2 COVID-19 trial which enrolled a unique patient population that is rarely targeted for clinical research.